Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Rhythm Pharmaceuticals, Inc.
RYTM
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.6B
$114.17
▲ +3.41%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$64.65 - $122.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 65.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage with FDA-approved IMCIVREE for rare genetic obesity
- Specialized expertise in melanocortin-4 receptor pathway and monogenic obesity genetics
- Established clinical relationships and research collaborations including Bardet-Biedl syndrome registry
- Focused pipeline addressing underserved rare disease markets with limited competition
Bear Case
2 risks
- Above-average volatility (beta 1.9).
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Strong growth ahead
IMCIVREE market expansion and patient identification in rare obesity indications
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+27.9% over 3m
Quality
Excellent
High-growth business (59% revenue growth, 89% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying RYTM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
MAY 5, 2026
Reported EPS of -$0.83 vs -$0.86 consensus (+3.5% surprise). Revenue of $60.1M vs $55.8M expected (+7.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+3.5%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
+73%
+26%
+67%
+54%
+37%
+84%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$29.1M
$33.3M
$41.8M
$32.7M
$48.5M
$51.3M
$57.3M
$60.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-92.6%
Wall Street consensus
11 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$143.00
▲ +25.3% vs $114.17
Latest: TD Cowen · Jun 17, 2026
1 analyst covering